Nexium could face early generic challenge, say analysts
AstraZeneca's Nexium could face generic competition much sooner than expected, and would-be investors should be wary, said brokerage firm Sanford C. Bernstein in an analyst note.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.